Onsdag 3 December | 16:35:34 Europe / Stockholm
Svenska | English

BioStock

Prenumeration

Vem äger bolaget?

All ägardata du vill ha finns i Holdings!

Sprint Bioscience: ”We have shown it's possible to make early deals”
2025-11-27 14:17:00

Sprint Bioscience recently sold its TREX1 program to Gilead. In an interview with BioStock, CEO Johan Emilsson explains the background to the deal, the strategic considerations that led to the transaction, and how the capital strengthens the company's ability to pursue its remaining programs. He also comments on the potential of the TREX1 project in immuno-oncology and what the deal means for the company's continued work.

See the interview biostock.se:
Sprint Bioscience: ”We have shown it is possible to make early deals”
 
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

Follow BioStock
Stay up to date with the latest news, upcoming events, recent videos, and podcasts! Subscribe to our newsletters at https://www.biostock.se/newsletter 
Follow BioStock on social media: LinkedIn and Facebook!  
 
About BioStock 
BioStock is the leading digital hub for the Nordic life science sector. Focusing on biotechnology, medical technology, diagnostics, and drug development, we provide daily news updates, in-depth analyses, exclusive interviews, and innovation-promoting networking events – all to keep you informed about industry developments.  
BioStock – Connecting Innovation & Capital. 

Källa MFN
Enter your email address and you will get a mail for verification you subscription to content on this page and filter


Select the time zone location for site wide time

Europe
London
Oslo
Stockholm
Helsinki

America
New York / Eastern
Chicago / Central
Los Angeles / Western

Ett mail har skickats till den givna adressen. För att logga in, klicka på "Login" i mailet för att verifiera ditt konto

Företag

Pressmeddelanden